A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.
🦱 탈모
🔵 RCT
무작위 임상시험
4/5 보강
TL;DR
Data from a patient questionnaire demonstrated that 5% topical minoxidil helped improve patients' psychosocial perceptions of hair loss in men with androgenetic alopecia as well as boosting hair regrowth in this 48-week trial.
📑 코퍼스 인용 관계
· 인용됨 79
📑 인용한 논문 (6) ▾
- Efficacy, Safety, and Tolerability of a Wearable Electrotrichogenic Device in Men with And… Dermatology and therapy · 2026
- Patient Satisfaction, Side Effects, and Other Reactions Reported by Adult Men Prescribed C… JMIR dermatology · 2026
- Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation… American journal of clinical dermatology · 2026
- Secondary Cutis Verticis Gyrata Induced by Long-Term Use of High-Dose Topical Minoxidil. Skin appendage disorders · 2025
- Can oral minoxidil be the game changer in androgenetic alopecia? A comprehensive review an… Skin health and disease · 2025
- Topical minoxidil for androgenetic alopecia: When blood pressure agents make you hairy. Canadian family physician Medecin de famille canadien · 2025
연도별 인용 (2012–2026) · 합계 329
OpenAlex 토픽 ·
Hair Growth and Disorders
Ovarian function and disorders
Facial Rejuvenation and Surgery Techniques
Abstract 🌐 Abstract
[BACKGROUND] Topical minoxidil solution 2% stimulates new hair growth and helps stop the loss of hair in individuals with androgenetic alopecia (AGA). Results can be variable, and historical experience suggests that higher concentrations of topical minoxidil may enhance efficacy.
[OBJECTIVE] The purpose of this 48-week, double-blind, placebo-controlled, randomized, multicenter trial was to compare 5% topical minoxidil with 2% topical minoxidil and placebo in the treatment of men with AGA.
[METHODS] A total of 393 men (18-49 years old) with AGA applied 5% topical minoxidil solution (n = 157), 2% topical minoxidil solution (n = 158), or placebo (vehicle for 5% solution; n = 78) twice daily. Efficacy was evaluated by scalp target area hair counts and patient and investigator assessments of change in scalp coverage and benefit of treatment.
[RESULTS] After 48 weeks of therapy, 5% topical minoxidil was significantly superior to 2% topical minoxidil and placebo in terms of change from baseline in nonvellus hair count, patient rating of scalp coverage and treatment benefit, and investigator rating of scalp coverage. Hair count data indicate that response to treatment occurred earlier with 5% compared with 2% topical minoxidil. Additionally, data from a patient questionnaire on quality of life, global benefit, hair growth, and hair styling demonstrated that 5% topical minoxidil helped improve patients' psychosocial perceptions of hair loss. An increased occurrence of pruritus and local irritation was observed with 5% topical minoxidil compared with 2% topical minoxidil.
[CONCLUSION] In men with AGA, 5% topical minoxidil was clearly superior to 2% topical minoxidil and placebo in increasing hair regrowth, and the magnitude of its effect was marked (45% more hair regrowth than 2% topical minoxidil at week 48). Men who used 5% topical minoxidil also had an earlier response to treatment than those who used 2% topical minoxidil. Psychosocial perceptions of hair loss in men with AGA were also improved. Topical minoxidil (5% and 2%) was well tolerated by the men in this trial without evidence of systemic effects.
[OBJECTIVE] The purpose of this 48-week, double-blind, placebo-controlled, randomized, multicenter trial was to compare 5% topical minoxidil with 2% topical minoxidil and placebo in the treatment of men with AGA.
[METHODS] A total of 393 men (18-49 years old) with AGA applied 5% topical minoxidil solution (n = 157), 2% topical minoxidil solution (n = 158), or placebo (vehicle for 5% solution; n = 78) twice daily. Efficacy was evaluated by scalp target area hair counts and patient and investigator assessments of change in scalp coverage and benefit of treatment.
[RESULTS] After 48 weeks of therapy, 5% topical minoxidil was significantly superior to 2% topical minoxidil and placebo in terms of change from baseline in nonvellus hair count, patient rating of scalp coverage and treatment benefit, and investigator rating of scalp coverage. Hair count data indicate that response to treatment occurred earlier with 5% compared with 2% topical minoxidil. Additionally, data from a patient questionnaire on quality of life, global benefit, hair growth, and hair styling demonstrated that 5% topical minoxidil helped improve patients' psychosocial perceptions of hair loss. An increased occurrence of pruritus and local irritation was observed with 5% topical minoxidil compared with 2% topical minoxidil.
[CONCLUSION] In men with AGA, 5% topical minoxidil was clearly superior to 2% topical minoxidil and placebo in increasing hair regrowth, and the magnitude of its effect was marked (45% more hair regrowth than 2% topical minoxidil at week 48). Men who used 5% topical minoxidil also had an earlier response to treatment than those who used 2% topical minoxidil. Psychosocial perceptions of hair loss in men with AGA were also improved. Topical minoxidil (5% and 2%) was well tolerated by the men in this trial without evidence of systemic effects.
- 표본수 (n) 157
Data from a patient questionnaire demonstrated that 5% topical minoxidil helped improve patients' psychosocial perceptions of hair loss in men with androgenetic alopecia as well as boosting hair regro
APA 7
Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., & Trancik, R. J. (2002). A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men.. Journal of the American Academy of Dermatology, 47(3), 377-85. https://doi.org/10.1067/mjd.2002.124088
Vancouver
Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Jour. Amer. Acad. Derm.. 2002;47(3):377-85. doi:10.1067/mjd.2002.124088
AMA 11
Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, et al. A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. Jour. Amer. Acad. Derm.. 2002;47(3):377-85. doi:10.1067/mjd.2002.124088
Chicago
Olsen, E. A., Dunlap, F. E., Funicella, T., Koperski, J. A., Swinehart, J. M., Tschen, E. H., and Trancik, R. J.. 2002. "A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men." Journal of the American Academy of Dermatology 47 (3): 377-85. https://doi.org/10.1067/mjd.2002.124088
MLA 9
Olsen, E. A., et al. "A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men." Journal of the American Academy of Dermatology, vol. 47, no. 3, 2002, pp. 377-85. doi:10.1067/mjd.2002.124088.
PMID
12196747 ↗
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 7/8 (88%)
· 참조 0편 · 후속 7편
이 논문을 인용한 후속 연구 20
- Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considera…
- Minoxidil and its use in hair disorders: a review.
- Androgenetic Alopecia: Therapy Update.
- Androgenetic Alopecia: An Update of Treatment Options.
- Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair los…
- Evaluation of Not-Activated and Activated PRP in Hair Loss Treatment: Role of Growth Factor and Cyto…
- Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment o…
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.
- The Diagnosis and Treatment of Hair and Scalp Diseases.
- Alopecia Areata: An Updated Review for 2023.
- A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-der…
- A Study to Compare the Efficacy of Platelet-rich Plasma and Minoxidil Therapy for the Treatment of A…
- The Biology and Genomics of Human Hair Follicles: A Focus on Androgenetic Alopecia.
- Advances in hair growth.
- An Open-Label Randomized Multicenter Study Assessing the Noninferiority of a Caffeine-Based Topical …
- Innovative method of alopecia treatment by autologous adipose-derived SVF.
- Efficacy of Asymmetric siRNA Targeting Androgen Receptors for the Treatment of Androgenetic Alopecia…
- Status of research on the development and regeneration of hair follicles.
- Hair Growth-Promoting Effect of Resveratrol in Mice, Human Hair Follicles and Dermal Papilla Cells.
- Efficacy and safety of combinational therapy using topical minoxidil and microneedling for the treat…
같은 제1저자의 인용 많은 논문 (5)
- The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride.
- A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men.
- SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss.
- Evaluation and treatment of male and female pattern hair loss.
- Objective outcome measures: Collecting meaningful data on alopecia areata.